Results 121 to 130 of about 1,875,199 (316)

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Lipopolysaccharide Increases Immune Activation and Alters T Cell Homeostasis in SHIVB’WHU Chronically Infected Chinese Rhesus Macaque

Journal of Immunology Research, 2015
Immune activation plays a significant role in the disease progression of HIV. Microbial products, especially bacterial lipopolysaccharide (LPS), contribute to immune activation.
Gao-Hong Zhang, Run-Dong Wu, Hong-Yi Zheng, Xiao-Liang Zhang, Ming-Xu Zhang, Ren-Rong Tian, Guang-Ming Liu, Wei Pang, Yong-Tang Zheng   +8 more
doaj   +1 more source

Animal Models of Alzheimer’s Disease: Utilization of Transgenic Alzheimer’s Disease Models in Studies of Amyloid Beta Clearance [PDF]

, 2012
Glial cells in Alzheimer’s disease (AD) have been shown to be capable of clearing or at least restricting the accumulation of toxic amyloid beta (Aβ) deposits.
Jari Koistinaho, Johanna Magga, Tarja Malm   +2 more
core   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Bayer AG v. Housey Pharmaceuticals: Protection for Biotechnological Research Tools under Section 271(g) Found Wanting [PDF]

, 2005
[Excerpt] Research tools, a subset of biotechnological inventions protected by process patents, are “tools that scientists use in the laboratory, including cell lines, monoclonal antibodies, reagents, animal models, growth factors, combinatorial ...
Barthalow, Matthew
core   +1 more source

Down syndrome-recent progress and future prospects [PDF]

, 2009
Down syndrome (DS) is caused by trisomy of chromosome 21 (Hsa21) and is associated with a number of deleterious phenotypes, including learning disability, heart defects, early-onset Alzheimer's disease and childhood leukaemia.
Adams, Adayev, Ahn, Ait Yahya-Graison, Altafaj, Antonarakis, Arron, Aylward, Aylward, Bartel, Belichenko, Bercovich, Best, Bliss, Brault, Canfield, Canzonetta, Carothers, Clark, Contestabile, Costa, de Graaf, De Vita, Denoeud, Dowjat, Draheim, E. M.C. Fisher, Ermak, Ermak, F. K. Wiseman, Fernandez, Freeman, Fuentes, Gerstein, Glasson, Granholm, Granholm, Groet, Guidi, Gwack, Harashima, Hasle, Hassold, Hill, Holland, Holtzman, Holtzman, Hunter, Hunter, Izraeli, Janicki, Johannsen, K. A. Alford, Kiyoi, Klusmann, Kuhn, Lai, Lee, Liang, Loos, Lorenzi, Mart  nez de Lagr  n, Maslen, Meng, Moore, Morice, Morris, Morrison, Murthy, Necchi, Nistor, O'Doherty, O'Donovan, O'Nuallain, Olson, Park, Pearlson, Prandini, Richtsmeier, Ryoo, Sato, Seo, Sethupathy, Stefansson, Sultan, Sussan, Toso, Tybulewicz, V. L.J. Tybulewicz, Wahab, Walters, Wechsler, Wegiel, Weis, Williams, Woods, Yang   +96 more
core   +2 more sources

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Animal models of celiac disease. Usefulness and limitations [PDF]

, 2016
PòsterJun
Ortega Puente, Sara, Universitat Autònoma de Barcelona. Facultat de Veterinària   +1 more
core  

Gene Therapy for Cardiovascular Disease [PDF]

, 2003
The last decade has seen substantial advances in the development of gene therapy strategies and vector technology for the treatment of a diverse number of diseases, with a view to translating the successes observed in animal models into the clinic ...
Baker, Andrew H., Denby, Laura, Dishart, Kate L., Work, Lorraine M.   +3 more
core   +4 more sources

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source